PO.ET01.03 · 实验与分子治疗
Next-Generation Targeted Therapies Directed Against Tumor Surface Antigens
- 4533 4533 Discovery and characterization of CARs against novel, highly selective solid tumor targets identified using the Oncolinkage platform McKensie Collins, Benjamin Hallisey, Andrew Astley, Murray O. Robinson
-
-
-
-
- 4539 4539 A MUC1-C-targeting ADC exhibits potent antitumor activity against neuroendocrine prostate cancer in both intact and testosterone-depleted preclinical models Surender Kharbanda, Rehan Ahmad, Deepak Raina, Changchuin Mao, Sourav Choudhary, Brian Lawney, Nandita Sreenivasalu, Govind Panchamoorthy, Neeraj Agarwal, Ravi Jasuja
- 4540 4540 BC602: An IND-enabling stage LGR5x EGFR bispecific antibody with superior anti-tumor efficacy in mouse CDX and PDX models Zhe Shao, Tao Wang, Wen Chao Jia, Keng Hoe Lok, Zhong Zong Pan
-
-
- 4543 4543 A novel CDH17-targeted radioligand therapy overcomes resistance to microtubule and topoisomerase I inhibitor ADCs and achieves potent efficacy in GI-tract tumors Abdul Mondal, Garima Kaushik, Marina Bell, Maxwell Hilbert, Arnab Mukharjee, Dennis Beckford, Paul Heverly, Michael Ritchie, Kakajan Komurov
- 4544 4544 Predictive biomarkers and combination strategies to overcome resistance to HER2- and TROP2-directed antibody drug conjugates with topoisomerase I inhibitor payloads in SCLC Kavya Ramkumar, C. Allison Stewart, Shui-Ping So, Runsheng Wang, Azusa Tanimoto, Alberto Duarte Jr., Jenna H. Gray, Li Shen, Lixia Diao, Yuanxin Xi, Qi Wang, Alejandra G. Serrano, Luisa M. Solis Soto, Jing Wang, Bingnan Zhang, Carl M. Gay, Lauren A. Byers
-
- 4546 4546 HER2- and TROP2-antibody-drug conjugates in small cell lung cancer cell lines and 3D culture: Efficacy and role of target expression Jenna Gray, Kavya Ramkumar, C. Allison Stewart, Runsheng Wang, Alberto Duarte, Azusa Tanimoto, Robert J. Cardnell, Lauren Averett Byers, Carl M. Gay
- 4547 4547 TRO-02, a conditionally activated EGFR-targeting ADC incorporating TROCAD TM and TROSIG TM platforms, shows enhanced tumor selectivity and potent efficacy Young Hun Lee, Do Hyeon Kim, Eun Young Shim, Eunhyun Choi, Jong Un Cho, Myoungki Baek, Sung Ho Woo
- 4548 4548 Therapeutically targeting B7-H6 with antibody-drug conjugates for diffuse large B-cell lymphoma Qiaoling Ye, Ye Lu, Chulin Sha, Peng Guo
- 4549 4549 Discovery of HMPL-A580, a first-in-class antibody-targeted therapy conjugate (ATTC) of a novel PI3K/PIKK inhibitor payload linked to an anti-EGFR antibody Yu Cai, Xiangling Chen, Shishuang Chen, Na Yang, Yan Xu, Huijing Yu, Shiming Fan, Haibin Yang, Min Cheng, Nelson Ng, Jianlin He, Shaohui Shen, Weigang He, wei shao, xiaoming dai, Yajing Bai, Yizhen Yang, linfang wang, Jian Wang, Weihan Zhang, Yongxin Ren, Guangxiu Dai, Michael Shi, Weiguo Su
-
-
- 4552 4552 BSI-730, a first-in-class HER2xPD-L1 bi-specific ADC, demonstrates potent anti-tumor activity in HER2-low models via selective tumor cell killing and immune modulation Hui-Han Hu, Xiaoyao Hao, Yue Gao, Hongyan Li, Jinyu Liu, Jinge Zhao, Yi Lu, Liezhou Ji, Zhigang Ma, Mingjiu Chen, Kedan Lin
- 4553 4553 BSI-128 (AK2024) enhances trastuzumab function and potentiates trastuzumab-deruxtecan activity across HER2-positive preclinical models Hui-Han Hu, Yinghui Dou, Hongyan Li, Liansheng Cheng, Jinyu Liu, Li Wei, Wenwen Dai, Daoqin Liu, Hui Wang, Ting Xu, Xiaoyao Hao, Yue Gao, Jinge Zhao, Yi Lu, Mingjiu Chen, Kedan Lin
-
